- The current standard for bladder cancer visualization, white light, is over three decades old and used in 95% of the bladder cancer surgeries
- The recurrence rate of bladder cancer is more than 50% due to the inability to see clear margins in the white light surgical standard for visualization
- Imagin Medical Inc.’s proprietary i/Blue(TM) System changes the way that surgeons visualize bladder cancer with side-by-side imaging of white and blue light pictures on one screen
- Blue light procedures are capable of reducing recurrence rates by 12-43% depending on the type, stage, and grade of bladder cancer
- The global bladder cancer market is expected to reach $4.71 billion in 2026
Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard for the visualization of cancer during minimally invasive surgeries (“MIS”). The company’s current focus is bladder cancer, the most expensive cancer to treat due to a high recurrence rate (50 percent), leaving approximately 600,000 people in the United States living in fear that their cancer will return.
The current standard for visualizing bladder cancer is white light during cystoscopies, a three-decade old technology and used in more than 95 percent of interventions. Cystoscopies use white light to visualize the tumor on the bladder’s surface. The problem with the white light is that it is only effective for the cancerous tumors that protrude above the bladder wall. For the flat margins, it is almost impossible to see them with white light alone.
The American Urology Association recommended the use of blue light, combined with an FDA approved fluorescing imaging agent, to their guidelines for bladder cancer detection. Blue light, used with contrast agents, can help with easier detection of flat tumors and the margins for more successful resection. Depending on the type of bladder cancer, blue light cystoscopies can help reduce recurrence rates by 12-43 percent as enhanced visibility allows for a more efficient resection of tumors (https://nnw.fm/kwd5E).
However, the blue light used by surgeons in the field today is only available from one scope manufacturer, and doesn’t show images in real time, requiring surgeons to constantly switch between white and blue light during interventions.
Imagin Medical’s i/Blue(TM) Imaging System can correct the limitations of today’s white and blue light cystoscopy procedures. The innovative technology allows the surgeon to see the real-time white light image, side-by-side with the blue light image on the screen simultaneously during a procedure. Additionally, the technology is highly versatile and can be attached to most endoscope model available on the market, which means hospitals would be able to adopt the innovative visualization system without having to replace their current instruments, resulting in significant cost savings.
Bladder cancer is the sixth most prevalent type of cancer in the United States. It is estimated that the number of new bladder cancer cases in 2020 reached 81,400, which accounts for 4.5% of all new cancer cases. The estimated number of deaths in 2020 equaled 17,980, accounting for 3% of all cancer deaths (https://nnw.fm/ggDRe). According to Verified Market Research, the global cancer market was valued at $3.43 billion in 2018 and is expected to reach $4.71 billion in 2026 (https://nnw.fm/3GGdp).
Led by a management team with significant experience in the market, both in medical device implementation and MIS, Imagin Medical is confident that its technology has the potential to revolutionize the current standard of care for bladder cancer patients, positioning the company as a leading provider of effective solutions in the vast market of bladder cancer visualization.
For more information, visit the company’s website at www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://nnw.fm/IMEXF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
